Enable Injections announced today that it partnered with Serina Therapeutics to develop therapeutics for the enFuse delivery system. The companies aim to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse to treat Parkinson’s disease. This deal builds upon a recent agreement that allows Roche to obtain a worldwide, exclusive license to develop and commercialize […]
Pharmaceuticals
Carthera wins U.S., EU orphan drug designation for SonoCloud
Carthera announced today that it received FDA and European orphan drug designation (ODD) for the use of carboplatin with its SonoCloud. The designation allows Paris, France-based Carthera to use carboplatin chemotherapy in the treatment of malignant glioma. Carthera conducts this treatment through the use of SonoCloud, a device that emits ultrasound to temporarily increase the […]
Enable Injections, Roche expand enFuse delivery partnership
Enable Injections announced today that it expanded its collaboration with Roche to utilize its enFuse delivery technology in development programs. The partnership allows Roche to develop and apply Enable Injections’ expertise and enFuse technology to specific development programs. Through the collaboration, Roche can obtain a worldwide, exclusive license to develop and commercialize combinations of enFuse […]
Xeris, Beta Bionics collab on glucagon product for pumps
Xeris and Beta Bionics today announced an exclusive worldwide collaboration to develop a glucagon product for proprietary pump technology. The collaboration and license agreement covers the development and commercialization of a glucagon product utilizing the Xeris XeriSol technology. Xeris and Beta Bionics aim to utilize the product with proprietary bi-hormonal pump and pump systems. Glucagon, […]
Eli Lilly acquires new injectable medicine manufacturing plant
Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the […]
Ypsomed, ten23 health collab on YpsoDose patch injector
Ypsomed announced today that it entered into a partnership with ten23 health to commercialize its YpsoDose wearable injector. Burgdorf, Switzerland-based Ypsomed designed YpsoDose for the subcutaneous self-injection of large-volume doses. ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute to the product offering. The strategic collaboration sees both parties […]
Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
Abbott (NYSE:ABT) today announced data from two real-world studies highlighting the success of its CGM when used with GLP-1 drugs. Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes […]
Vivani has positive data for long-term drug-eluting weight loss implant as it shifts strategy
Vivani Medical (Nasdaq:VANI) today announced positive pre-clinical data on weight loss effects for its long-term exenatide implant. Alameda, California-based Vivani has its miniature, twice-yearly exenatide implant — NPM-115 — under development to treat chronic weight management. The company also disclosed that it included semaglutide as the active pharmaceutical ingredient in its NPM-139 subdermal GLP-1 implant […]
Narcan nasal spray maker Emergent BioSolutions has a new CEO
Emergent BioSolutions (NSYE:EBS) announced today that it appointed Joseph C. Papa as its new president and CEO. Papa’s appointment to the corner office of the Gaithersburg, Maryland-based company went into effect today. He succeeds Haywood Miller, who stepped down from his role as interim CEO today as well. Emergent BioSolutions is known for its Narcan […]
Carthera enrolls first patient in ultrasound drug delivery trial
Carthera announced today that it enrolled the first patient in the SONOBIRD pivotal trial for its SonoCloud device. Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery. After implantation in the skull, […]
